These Analysts Lower Their Forecasts On Revance Therapeutics After Q1 Results
These Analysts Lower Their Forecasts On Revance Therapeutics After Q1 Results
Revance Therapeutics, Inc. (NASDAQ:AKAM) posted a loss for its first quarter on Thursday.
Revance Therapeutics, Inc.（纳斯达克股票代码：AKAM）周四公布了第一季度亏损。
Revance Therapeutics posted a GAAP loss of 54 cents per share, compared to market expectations for a loss of 63 cents per share. The company's quarterly sales came in at $51.936 million versus estimates of $56.634 million, according to data from Benzinga Pro.
Revance Therapeutics公布的每股GAAP亏损为54美分，而市场预期的每股亏损为63美分。根据Benzinga Pro的数据，该公司的季度销售额为5193.6万美元，而预期为5,663.4万美元。
"We are very pleased to see the DAXXIFY strategy change continue to drive the desired momentum and market share gains. Notably, we saw a healthy uptick in volume both on a year-on-year basis, where aesthetic units sold increased by 105%, and on a sequential quarterly basis where aesthetic units sold increased by 7% despite traditional Q4 to Q1 seasonality. The positive impact of our strategy change was further reflected in our market share gains where DAXXIFY's share increased from 3.0% in Q4'23 to 3.7% in Q1'24.1 DAXXIFY's net revenue was $22.1 million for the quarter, after a reduction of $2.0 million related to a consumer coupon program. In addition, the RHA Collection continued to outpace the market growing share from 9.1% in Q4'23 to 9.8%1 in Q1'24, against the backdrop of a soft filler market," said Mark J. Foley, President and Chief Executive Officer.
“我们很高兴看到DAXXIFY的战略变化继续推动预期的势头和市场份额的增长。值得注意的是，我们的销量同比增长良好，美学单位的销量增长了105％，而美学单位的销量连续季度增长了7％，尽管有传统的第四季度至第一季度的季节性。我们的战略变更的积极影响进一步反映在我们的市场份额增长上，DAXXIFY的份额从23年第四季度的3.0％增加到24年第一季度的3.7％。在与消费者优惠券计划相关的200万美元之后，DAXXIFY本季度的净收入为2,210万美元。此外，在软填料市场的背景下，RHA系列继续超过市场增长份额，从23年第四季度的9.1％增至24年第一季度的9.8％1。” 总裁兼首席执行官马克·弗利说。
Revance continues to expect 2024 total net product revenue, which includes sales of DAXXIFY and RHA collection, to be at least $280 million.
Revance继续预计，2024年的总净产品收入，包括DAXXIFY和RHA系列的销售，将达到至少2.8亿美元。
Revance Therapeutics shares rose 0.5% to close at $4.29 on Thursday.
周四，Revance Therapeutics股价上涨0.5％，收于4.29美元。
These analysts made changes to their price targets on Revance Therapeutics following earnings announcement.
财报公布后，这些分析师调整了Revance Therapeutics的目标股价。
- Needham cut the price target on Revance Therapeutics from $18 to $12. Needham analyst Serge Belanger maintained a Buy rating.
- Mizuho slashed the price target on Revance Therapeutics from $9 to $8. Mizuho analyst Vamil Divan maintained a Neutral rating.
- 尼德姆将Revance Therapeutics的目标股价从18美元下调至12美元。尼德姆分析师塞尔吉·贝兰格维持买入评级。
- 瑞穗将Revance Therapeutics的目标股价从9美元下调至8美元。瑞穗分析师瓦米尔·迪万维持中性评级。
Read More: Top 2 Materials Stocks That Could Blast Off This Quarter
阅读更多：本季度可能暴跌的两大材料股